BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IAS-USA//NONSGML PDA Calendar Version 1.0//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:7be3e8e9928ac39336afaacfaf424fc3
ORGANIZER:registration@iasusa.org
DTSTAMP:20261026T204221Z
LOCATION:
SUMMARY:Basics of HIV Drug Resistance Mutations
DESCRIPTION:[vc_row][vc_column][vc_message]This is the rescheduled date for our postponed October 27\, 2022\, webinar. If you have previously registered for the prior date\, your registration has automatically been converted.[/vc_message][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]\n\nOverview\n\nAssessment of Needs\nThis webinar will review the basic principles of HIV drug resistance mutations and highlight the recent IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1\, released in September 2022. It will provide an overview of the article\, particularly on understanding and applying the information in clinical practice. Additionally\, it will discuss the recent update\, including new drugs such as lenacapavir and doravirine\, and how to manage drug resistance in patients.\nLearning Objectives\nUpon completion of this activity\, learners will be able to:\n\n 	Describe basic principles of HIV drug resistance mutations\n 	Explain how to understand and interpret the information presented on the IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1\n 	Identify recent updates to the IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1 and how they apply to the management of drug resistance in patients\n\nRegistration\nWho Should Attend\nThis webinar is designed for clinical decision makers who are actively involved in HIV care and research\, including physicians\, physician assistants\, nursing professionals\, pharmacists\, and other health care professionals.\n\nIndividual registration is required in order to receive CME credit or a certificate of participation.\n\nRegistration closes on December 14\, 2022\, 10:30 AM (PT).\n\nCertificates will be available after the completion of the evaluation and claim form.\n\nFor more information or questions\, please contact the registration department at registration@iasusa.org or 415-544-9400.\nConflicts of Interest\nIn the interest of maintaining the independence of its continuing medical education (CME) activities\, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg\, faculty\, Scientific Leadership Board\, Governance Board\, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  \n\nThe Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as "those whose primary business is producing\, marketing\, selling\, re-selling\, or distributing healthcare products used by or on patients.” \n\nIAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content. \n\nPresenters\n\nDr Ceccherini-Silberstein has been a consultant to Gilead Sciences\, Inc\, Merck Sharp &amp\; Dohme\, Inc\, Theratechnologies\, Inc\, ViiV Healthcare\, and has received research grants from Gilead Sciences\, Inc\, Merck Sharp &amp\; Dohme\, Inc.\, and ViiV Healthcare (Updated 12/14/22)\n\nDr Richman has served on a scientific advisory board for Antiva Biosciences\, Assembly Biosciences\, Inc.\, Generate Biomedicines\, IGM Biosciences\, Inc.\, and serves as Chair of the Data Management Committee of Gilead Sciences\, Inc. (Updated 12/14/22)\n\nDr Shafer has served on advisory boards for Gilead Sciences\, GlaxoSmithKline\, and Vir Biotechnology. He has received payment for lectures from Gilead Sciences\, ViiV Healthcare\, and GlaxoSmithKline. (Updated 12/14/22)\n\nPlanner/Reviewer\n\nPlanner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (12/14/22)\nPlanner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (12/14/22)\n\n&nbsp\;\n\n\n\n\n\nCME Credits\nThe International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\n\nThe IAS–USA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nABIM MOC Points\nSuccessful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA\, the CME activity provider\, will submit your participant information (eg\, name\, date of birth\, activity credits earned\, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.\nNursing Credits\nEducational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association\, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 1.5 hours of continuing nursing education.\n\nEducational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692)\, the state of Florida and the District of Columbia.\nPharmacy Credits\n Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.5 contact hours (0.15 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event\, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.\nUAN  # 0761-9999-22-454-L02-P\nGrant Support\n\n\nThis activity is part of the IAS–USA national educational effort that is funded\, in part\, by charitable contributions from ineligible companies. Per IAS–USA policy\, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity\, including its content\, development\, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.\n\nPLATINUM SUPPORTERS\n\nGilead Sciences\, Inc.\nMerck &amp\; Co\, Inc.\nViiV Healthcare\n\nSILVER SUPPORTER\n\nJanssen Therapeutics\n\nBRONZE SUPPORTER\n\nTheratechnologies\, Inc.\n\n&nbsp\;\n\n\nFrequently Asked Questions\nView our list of FAQs about attending a webinar.\n\nFurther Questions?\nPlease contact the registration department at registration@iasusa.org or 415-544-9400.\n\n\n\n[/vc_column_text][/vc_column][/vc_row]
STATUS:CONFIRMED
CATEGORIES:Webinars
URL;VALUE=URI:https://www.iasusa.org/events/webinar-2022-muta/
DTSTART:20221214T180000Z
DTEND:20221214T193000Z
END:VEVENT
END:VCALENDAR